Pharmafit Provence
ACTICARBINE Coated tab Blister/84

Elerté

ACTICARBINE Coated tab Blister/84

CIP / EAN code: 3400934312908

Product information from VIDAL.

Read the product information

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of 20/09/2013

ACTICARBINE, coated tablet


Forms and presentations

Coated tablet


Composition

Activated charcoal ....................................................................................................................................................70,000 mg

Papaverine hydrochloride ..............................................................................................................................14,000 mg

For one coated tablet


Excipients:

Alginic acid, sucrose, corn starch, liquid glucose, polyethylene glycol 6000, magnesium stearate, bleached shellac, talc, gum arabic, titanium dioxide, carnauba wax



Indications

Symptomatic treatment of functional intestinal disorders, including with bloating.



Dosage and administration

Reserved for adults

1 to 2 tablets before 3 meals, to be swallowed whole with a glass of water.



Contraindications

This medicine must not be used in case of hypersensitivity to any of the constituents.

This medicine should generally not be used during pregnancy.



Warnings and precautions

In case of associated diarrhoea, the need for rehydration should be assessed.

The extent of rehydration by oral rehydration solution or by intravenous route must be adapted according to the intensity of the diarrhoea, the age and the particularities of the patient (associated diseases…).



Interactions

Due to the properties of charcoal, the potential reduction in drug absorption means that any other medication should be administered at a distance (more than 2 hours, if possible) from the intake of this medicine.



Fertility, pregnancy and breastfeeding

Pregnancy

In the absence of reliable experimental data and in the absence of clinical experience with papaverine, the use of this medicine is not recommended during pregnancy.

Breast-feeding

In the absence of data on the passage of papaverine into milk, this medicine should be avoided in case of breastfeeding.



Driving and using machines

Attention is drawn, particularly to drivers of vehicles and users of machinery, to the risks of drowsiness due to the presence of papaverine.



Adverse effects

The use of this medicine at high doses may cause darker discolouration of the stools.



Overdose

No cases of overdose have been reported with this medicine. Papaverine, at very high doses, risks causing nausea, vomiting, weakness, central nervous system depression, nystagmus, diplopia, diaphoresis, facial flushing, dry mouth, dizziness and sinus tachycardia.



Pharmacodynamics

Pharmacotherapeutic class:

INTESTINAL ADSORBENT

ANTISPASMODIC

(A: alimentary tract and metabolism)

Association of activated charcoal and papaverine



Shelf life

5 years



Special storage precautions

No special precautions for storage.



SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

No special requirements.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400934312786 (Fl/42).
CIP 3400934312908 (Fl/84).
Not reimbursed Social Security (Fl/42, Fl/84).

Elerté
181-183 RUE ANDRÉ KARMAN
93300 AUBERVILLIERS CEDEX
Tel: 01 48 34 75 03 laboratoire-elerte@orange.fr
https://www.elerte.fr/

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.